Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. BenevolentAI buys research facility to support drug development
  2. AstraZeneca buys licence to antisense drug for up to $330 million
  3. AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
  4. Will Amazon be the new face of healthcare?
  5. Takeda and Wave Life Sciences to develop neurological treatments

Latest Content

AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?

At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top